Every established practice eventually gets the call: an MSO, an aggregator, or a private-equity-backed platform offering simplicity in exchange for autonomy. The trade is real. Most groups price it wrong — in both directions.
Why the timing of the question matters more than the answer
The worst moment to develop a point of view on MSOs is in the meeting where one is presenting. By then the frame is theirs: their valuation model, their definition of “alignment,” their timeline. Groups that decide what they actually want before any suitor is in the room consistently negotiate better outcomes — including the outcome of declining.
The pressure is understandable. Reimbursement and payer-mix changes arrive faster than owners have time to model. Compliance load grows while the workday stays the same length. An offer that promises to take the business problems away has genuine appeal — which is precisely why it deserves disciplined scrutiny rather than relief-driven acceptance.
Five questions to resolve before the first conversation
1. What is the practice actually worth — to you?
Not the multiple the platform quotes; the value of the income stream, autonomy, and optionality you would surrender. A practice whose operations and revenue cycle have been tightened in the eighteen months before a transaction commands materially better terms than one selling in a state of administrative fatigue. Selling tired is selling discounted.
2. Which problems are you actually trying to solve?
List them specifically: payer contracting leverage, billing performance, recruiting, call burden, capital for expansion. Then ask, item by item: does this require selling control, or can it be bought, hired, or engaged? Many groups discover that two or three targeted fixes deliver most of what the MSO pitch promised — without the irreversible step.
3. What does governance look like on a bad day?
Every platform deck shows clinical autonomy preserved. The test is not the deck; it is the documents. Who controls staffing ratios, scheduling templates, equipment purchases, and payer participation when the platform’s budget and the physicians’ judgment disagree? The answer lives in the management services agreement and the governing documents — and it deserves to be read as if the honeymoon will end, because the relevant clauses only operate when it does.
4. What is the exit — yours and theirs?
Platforms have investment horizons; physicians have careers. Ask what happens at the platform’s next sale: do your economics roll, reprice, or dilute? And ask what your own exit looks like — restrictive covenants, repurchase rights, and the practical question of whether you could rebuild within your own market if the relationship failed. State law on physician covenants varies meaningfully; what is enforceable in one state is void in another, and your leverage depends on knowing which.
5. Is the structure compliant where you practice?
Corporate-practice-of-medicine doctrine, fee-splitting prohibitions, and state-specific MSO rules are not formalities; they determine whether the structure being offered is durable. A structure that works in the platform’s home state may sit differently in yours. The diligence question is simple to ask and revealing in the answer: show us how this structure has been adapted for our state, and who signed off on it.
The strongest negotiating position is a practice that does not need the deal — and can prove it with eighteen months of improving numbers.
If the answer is “not yet”
Declining the meeting is not declining forever. Groups that use the interval deliberately — tightening revenue-cycle performance, documenting operations, resolving the governance questions among the partners — enter any future process with leverage instead of fatigue. The same work that raises a future valuation also makes independence more sustainable, which means the work is worth doing regardless of which door the group ultimately walks through.
The question to put to your partners this quarter
If the strongest platform in our specialty called tomorrow, do we know — as a group, in writing — what we would need to see to say yes, and what would make us say no? If the answer is no, that conversation is worth having before the phone rings. It costs nothing, and it is the single highest-leverage hour a partnership can spend on the subject.
This article represents the professional opinion of GCX Health Inc. and does not constitute legal or financial advice. MSO structures, physician covenants, and corporate-practice-of-medicine rules are state-specific; engage qualified healthcare counsel before entering or restructuring any arrangement.